Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer

Soley Bayraktar, Sameer Batoo, Eyad Al-Hattab, Sandeep Basu, Scott Okuno, Stefan Glück

Research output: Contribution to journalReview articlepeer-review

Abstract

There are three US FDA-Approved CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib for patients with HR-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC). They are all equally effective, so the question becomes how to choose among these agents and how to sequence them. Other areas with active investigation include identifying predictive biomarkers for the selection of patients whom may benefit more from CDK4/6 inhibitors, deciding whether to continue CDK4/6 inhibitors after disease progression on CDK4/6 inhibitors, creating novel treatment combinations and expanding use beyond HR+/HER2-MBC. Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR+/HER2-MBC.

Original languageEnglish (US)
Pages (from-to)2661-2672
Number of pages12
JournalFuture Oncology
Volume16
Issue number32
DOIs
StatePublished - Nov 2020

Keywords

  • aromatase inhibitor
  • CDK4/6 inhibitors
  • faslodex
  • hormone-receptor positive
  • metastatic breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer'. Together they form a unique fingerprint.

Cite this